Polymyalgia Rheumatica
A syndrome in the elderly characterized by proximal joint and muscle pain, high erythrocyte sedimentation rate, and a self-limiting course. Pain is usually accompanied by evidence of an inflammatory reaction. Women are affected twice as commonly as men and Caucasians more frequently than other groups. The condition is frequently associated with GIANT CELL ARTERITIS and some theories pose the possibility that the two diseases arise from a single etiology or even that they are the same entity.
Drugs by status
Phase 4 trials (3)
Phase 3 trials (14)
Phase 2 trials (4)
Phase 1 trials (1)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (5)
Organization Involved with Phase 3 Indications (29)
- Abbott
- AbbVie
- Regeneron
- Bristol-Myers Squibb
- Schering-Plough
- Sanofi
- GlaxoSmithKline
- Mundipharma
- University of Pennsylvania
- University of Groningen
- University of South Florida
- Utrecht University
- University of Bristol
- University of Copenhagen
- University of Western Brittany
- University of Limoges
- University of Toulouse
- Medical University of Vienna
- University of Paris
- Valenciennes Hospital Centre
- Central Hospital Saint Quentin
- Dutch Health Care Insurance Board
- Rouen Normandy University
- University of Burgundy
- University of Picardie Jules Verne
- The Cleveland Clinic
- Reumafonds
- ZGT Almelo
- University of Cantabria
Organization Involved with Phase 2 Indications (18)
- Centocor
- Eli Lilly
- Genentech
- Novartis
- Analgesic Solutions
- Chugai
- Dinora, Inc.
- National Institutes of Health (NIH)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Rockefeller University
- University of Rochester
- University of Bern
- Mayo Clinic
- Peking University
- CHNO des Quinze-Vingts
- Janssen Pharmaceutica NV
- PharPoint Research, Inc.
- Kiniksa Pharmaceuticals, Ltd.
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (2)